A Small-Molecule Targets EGFR to Induce DNA Damage and Disrupt the EGFR-WEE1 Interaction in Glioblastoma

Jianzheng Huang[1], Zijun Zhang[1], Yang Xiao[1], Ziming Zhao[1], Zengwei Luo[1], Junjun Liu[1], Chao Song[2], Shouchang Feng[3], Suojun Zhang[3], Xingjiang Yu[2], Qingyi Tong[1*], Yonghui Zhang[1*]

[1]Department of Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China;

[2]Department of Histology and Embryology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;

[3]Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Corresponding Author: Yonghui Zhang, Department of Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Jianghan District, Wuhan, Hubei Province, 430030, China (zhangyh@mails.tjmu.edu.cn.); Qingyi Tong, Department of Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Jianghan District, Wuhan, Hubei Province, 430030, China (qytong@hust.edu.cn.);

Graphical abstract

Abstract

Glioblastoma (GBM) is a highly aggressive primary brain malignancy with limited therapeutic options, underscoring the urgent need for novel therapeutic agents. epidermal growth factor receptor (EGFR), a well-established oncogenic driver in GBM, remains a key therapeutic target due to its critical role in tumor progression and therapy resistance. ZYH005 (Z5), a small molecule with low systemic toxicity and enhanced blood-brain barrier penetration, warrants further investigation for its therapeutic efficacy and mechanisms in GBM. Here, we demonstrate that Z5 exhibits potent anti-proliferative effects against conventional GBM cell lines and patient-derived glioblastoma stem cells (GSCs), while significantly suppressing GSCs-induced orthotopic tumor growth and prolonging survival in murine models. Through Connectivity Map profiling, surface plasmon resonance, and mechanistic studies, we identify Z5 as a novel EGFR inhibitor that uniquely binds EGFR at E762 to induce DNA damage, subsequently impairing DNA repair mechanisms and disrupting EGFR-WEE1 interactions. This disruption suppresses WEE1 function, abrogates the G2/M checkpoint, and triggers mitotic catastrophe in GBM cells. Notably, we reveal a previously uncharacterized physical EGFR-WEE1 interaction in GBM, defining a new therapeutic axis. Structural analyses further suggest that the spatial orientation of E762 critically modulates EGFR-WEE1 complex formation. Collectively, these findings establish Z5 as a promising lead compound and provide a novel strategy for GBM drug development.

Statement of Significance: Our study identifies Z5 as a novel EGFR inhibitor that induces DNA damage and subsequently disrupts EGFR-WEE1 signaling , offering a novel therapeutic strategy for GBM.

Introduction

Glioblastoma multiforme (GBM) stands as the most invasive and deadly primary brain tumor among adults(1). It constitutes around 49% of all malignant central nervous system tumors. In high-income countries, its annual incidence is 3-7 cases per 100,000 individuals(2, 3). The treatment of GBM adopts a multimodal strategy, integrating surgery, radiotherapy, and temozolomide (TMZ)-based chemotherapy. However, the median survival time for GBM patients is a mere 12-16 months, and the 5-year survival rate remains below 5%(2, 3). The unrelenting therapeutic deadlock in neuro-oncology makes the development of novel drugs not just important, but an urgent medical necessity.

Epidermal growth factor receptor (EGFR) and its constitutively active mutant EGFRvIII are cardinal oncogenic drivers in GBM, with EGFR amplification present in more than 50% of tumors—predominantly the classical subtype(4). This genetic alteration activates pro-tumorigenic cascades (PI3K/AKT/mTOR, RAS/MAPK, JAK/STAT), collectively driving genome instability, angiogenesis, and invasive growth(5). In addition to activating downstream signaling pathways through ligand binding at the cell membrane, EGFR can also translocate into the nucleus, where it participates directly in DNA repair processes. Within the nucleus, EGFR forms functional interactions with DNA-dependent protein kinase catalytic subunit (DNA-PKcs), promoting its phosphorylation and thereby modulating DNA repair through the non-homologous end joining (NHEJ) pathway(6). Beyond this direct mechanism, EGFR exerts broader control over DNA repair processes by regulating the expression of key repair proteins XRCC1 and RAD51 through the RAS/RAF/MEK/ERK and PI3K/AKT signaling cascades. These multifaceted

EGFR-mediated adaptations collectively disrupt DNA damage response (DDR)

homeostasis, creating a permissive environment for tumor cells to evade cell cycle

checkpoints and survive genotoxic insults(7, 8). EGFR's central role in coordinating

DNA repair explains why its pharmacological inhibition impairs DDR pathways,

thereby sensitizing tumor cells to radiotherapy and other DNA-targeting therapies (9,

10). This has long established EGFR as a prime therapeutic target in GBM [11], while

highlighting the impact of EGFR inhibitors on DDR-related pathways and providing a

mechanistic rationale for their combination with other agents, including DDR-targeted

therapies(11). For instance, although EGFR tyrosine kinase inhibitors (TKIs)

demonstrate promising monotherapy efficacy, combination strategies—particularly

pairing EGFR-TKIs with MEK/PI3K inhibitors or DNA-damaging agents (e.g.,

temozolomide, radiotherapy)—achieve superior outcomes by exploiting temporal

vulnerabilities in DDR pathways. Preclinical studies further demonstrate that timed

EGFR-TKI administration ($\geq$4 hours before DNA damage induction) potentiates

tumor cell killing by prolonging DDR pathway disruption (12, 13). Thus, EGFR

remains a pivotal therapeutic target in GBM drug development due to its central

pathogenic role and druggability(11, 14, 15).

Phenanthridinone, a key heterocyclic scaffold widely found in bioactive alkaloids,

holds great potential for anti-tumor drug development(16, 17). Among its derivatives,

narciclasine and related analogs exhibit the strongest anticancer effects(18-20).

However, their natural scarcity limits drug research. We developed an efficient,

eco-friendly synthetic method for phenanthridone, enabling scalable derivative

production and overcoming supply challenges(21).Using this approach, we designed

and synthesized a series of phenanthridone derivatives, identifying ZYH005 (Z5) as

the lead candidate with superior anticancer efficacy over narciclasine(22). This

finding prompts us to systematically investigate Z5's anti-tumor effects and molecular

mechanisms, while also allowing us to draw insights from the preliminary studies on

narciclasine. Narciclasine exhibits selective in vivo efficacy against primary GBM

and brain-metastatic melanoma/lung cancer(18, 19), with efficient blood-brain barrier

(BBB) penetration attributed to its high lipophilicity, positioning it as a promising GBM therapeutic(20). Structurally, Z5 exhibits reduced hydrophilic (hydroxyl) groups, suggesting enhanced lipophilicity. In vivo BBB permeability assays in mice confirmed Z5's superior brain penetration compared to narciclasine (Supplementary Figures 1A-D). Given these pharmacokinetic advantages and structural optimizations, we hypothesized that Z5 may replicate or even exceed narciclasine's anti-GBM efficacy. Yet, the anti-GBM efficacy and mechanisms of this more potent phenanthridone derivative remain unexplored.

Here, we unveil Z5 as a novel EGFR inhibitor with potent anti-GBM activity—suppressing both bulk GBM cells and glioblastoma stem cells (GSCs) in vitro and in vivo. Our study breaks new ground by identifying Z5's mechanism: precise targeting of EGFR's E762 residue to trigger DNA damage, impair repair, and disrupt a previously unrecognized physical interaction between EGFR and WEE1. This disruption not only halts WEE1 function and abrogates the G2/M checkpoint but also drives catastrophic mitotic failure in GBM cells. By linking EGFR-WEE1 crosstalk to mitotic catastrophe, we uncover a novel therapeutic axis and position Z5 as a transformative lead compound for GBM treatment.

Materials and Methods

Compounds and cell lines

Z5 was synthesized in our laboratory, and its synthesis process has been described previously(22). U87-MG (RRID: CVCL_0022), U251-MG (RRID: CVCL_0021) and HEK293T (RRID: CVCL_0063) cell lines were purchased from Procell Life Science & Technology. DT40-related cell lines were gifts from Xiaohua Wu and Shunichi Takeda. GBM patient-derived GSCs (T3359 and D456) were gifted from Dr. Shideng Bao and Dr. Jeremy Rich(23). U87-MG, U251-MG and HEK293T cells were cultured in DMEM (Pricella, Wuhan, China) supplemented with 10% Fetal Bovine Serum (FBS) and 1% penicillin/streptomycin. DT40 cells were cultured in 1640 with 10% FBS, 1% Chicken Serum, 1% penicillin/streptomycin, 1% 200mM L-Glutamine and 0.1% β-mercaptoethanol(24). GSCs were cultured in a serum-free system containing

Neurobasal A basal medium supplemented with B-27 Supplement Minus Vitamin

A, l-glutamine, sodium pyruvate, 20 ng/ml recombinant epidermal growth factor, and

20 ng/ml basic fibroblast growth factor. Cell culturing, cryopreservation, and thawing

were all meticulously conducted in strict accordance with standard operating

procedures (SOPs). Short tandem repeat (STR) profiling and contamination

assessment of the cell lines were performed every six months. The results verified the

authenticity of the cell lines and confirmed their contamination-free status.

DNA Microarrays and Gene Set Enrichment Analysis (GSEA) analysis

Total RNA samples were extracted from U87-MG cells using the Trizol reagent

(Cat#15596-018, Life Technologies, Carlsbad, CA, US) reagent. RNA purification

was performed using the NucleoSpin RNA Clean-up XS kit (Cat#740903, MN,

Germany) and the RNase-Free DNase Set (Cat#79254, QIAGEN, GmBH, Germany).

According to the Affymetrix technical manual, the double-stranded cDNA was

hybridized with biotin-labeled fragmented cRNA. Microarray experiments were

performed using Affymetrix chips by Shanghai Biotechnology Corporation. Raw data

were normalized using the Expression Console algorithm in Command Console

Software 4.0 (Affymetrix, Santa Clara, CA, US). Differential expression analysis was

conducted using the affy package in R. Genes with an absolute log2 fold change >1

and a P-value <0.05 were considered differentially expressed. The microarray data for

U87-MG cells has been submitted to the NGDC/OMIX under accession number

OMIX008765. Significantly differentially expressed genes ($|Log2FC| \geq 1$, FDR ≤ 0.05)

are listed in **Supplementary Table S1**. All genes identified through DNA microarray

analysis were imported into GSEA software for further analysis and visualization.

Connectivity map (CMAP) analysis

Input the top 66 upregulated genes and 150 downregulated genes in supplementary S1

into the CMAP website (https://clue.io), query parameters were gene expression

(L1000), touchstone, individual query, 1.0. The detailed list was sorted by cell types

and perturbagen type was compound. The results obtained from CMAP are presented

in **Supplementary Tables S2-S11**.

Molecular Docking of Z5 with the EGFR Kinase Domain

For our molecular docking, we utilized the crystal structure of EGFR (PDB ID

7KXZ)(25). This structure was preprocessed using PDB2PQR program(26) to

determine the protonation state of titratable residues at pH=7, and was subsequently

converted to pdbqt format using the prepare_receptor4.py script from

AutoDockTools(27). Next, we prepared ZYH005 by converting compounds to pdbqt

format (pH 7.0) using OpenBabel. Using molecular docking scores as an indicator of

predicted binding affinity.

Limited Proteolysis–Mass Spectrometry (LiP-MS)

LiP-MS was performed as previously published(28). A detailed description is in

Supplementary Material.

Tissue Microarray and Immunohistochemistry

Tissue microarrays were obtained from Wuhan POWERFUL BIOLOGY Company

and approved by the Ethics Committee of Tongji Hospital of Tongji Medical College

of Huazhong University of Science and Technology (Serial number: 2021-lEC-A244).

The GBM tissue samples for TMA were prepared by dewaxing and antigen retrieval

prior to immunostaining. WEE1 antibody (Cell signaling technology, 1:200 dilution)

was used to detect the protein in the GBM tissue samples. IHC for in situ transplanted

mouse brain tissues was carried out using the same protocol as described above.

WEE1 antibody (Cell signaling technology, 1:200 dilution) and EGFR antibody

(Proteintech, 1:100 dilution) were used to detect the protein.

Orthotopic Transplantation mouse model assay

Experimental Balb/c nude mice were purchased from Beijing Vital River Laboratory

Animal Technology Co., Ltd (Beijing, China) and kept at the Experimental Animal

Center of Tongji Medical College, Huazhong University of Science and Technology,

Wuhan, China. All mice underwent phenobarbital sodium anesthesia before surgery.

One week after GSC ($2\text{x}10^4$ cells/mouse) was implanted in the right frontal lobe of

4-week-old mice, 15 mice were randomly divided into three groups: NT, Z5-L

(10mg/kg) and Z5-H (20mg/kg). The mice received either solvent (5% DMSO, 20%

castor oil, and 75% saline) or varying doses of the drug via gavage for 7 weeks. When

the NT group showed the first manifestation of obvious neurological signs, one mouse

from each of the remaining two groups was evaluated for drug efficacy. The

remaining 12 mice were used for survival studies.

Statistical analysis

Statistical analysis was performed using GraphPad Prism 9.0 software. The data were

expressed as the mean ± SD. We used paired t test for statistical analysis between 2

groups, and one-way ANOVA for multiple comparisons. All experiments were

repeated more than 3 times. We considered a p-value less than 0.05 to be statistically

significant.

Results

3.1 Z5 inhibits the proliferation and induces DNA damage in GBM cells

Quantitative viability assays demonstrated that Z5 potently inhibited GBM cell

proliferation in a time- and concentration-dependent manner, with 72-hour IC50

values of 0.114 ± 0.016 μM for U87-MG cells and 0.147 ± 0.049 μM for U251-MG

cells (Figure 1A). Z5 also significantly suppressed colony formation in both cell lines

(Figure 1B), while EdU incorporation assays further confirmed its marked inhibition

of DNA synthesis (Figures 1C-D). These anti-proliferative effects coincided with

clear evidence of DNA damage induction, as shown by increased DNA fragmentation

(Figure 1E) and elevated γ-H2AX expression—a sensitive marker of double-strand

breaks (Figure 1F)—consistent with Z5's established mechanism as a DNA

intercalator(22). Collectively, these findings establish Z5 as a potent cytotoxic agent against GBM cells that mediates its effects through robust inhibition of proliferation and induction of DNA damage.

Figure 1 Z5 inhibits the proliferation and induces DNA damage in GBM cells. (A) Cell viability was evaluated using CCK-8 kit after treated with Z5 for 24h, 48h and 72h. (B) The efficacy of Z5 in a colony formation assay was evaluated. (C) Fluorescent images of proliferating GBM cell lines in various treatment conditions (red: EDU staining; blue: Hoechst staining). (D) Quantification of the fluorescence of each group. Data are presented as the mean ± SD, n=3, compared with DMSO group. (E) Effect of Z5 on DNA fragment. (F) The expression of γ-H2AX was measured by immunoblotting after treatment with Z5.

3.2 Z5 induces G2/M arrest and mitotic catastrophe in GBM cells

To elucidate the molecular mechanisms underlying Z5's anti-GBM effects, we conducted a comprehensive microarray analysis, which identified 1,970 differentially expressed genes (188 upregulated and 1,782 downregulated) in Z5-treated U87-MG cells (Supplementary Figure 2A), with KPNA2, PRKDC, and MKI67 being the most significantly downregulated targets (Supplementary Figures 2B-C).

Subsequent KEGG, GO, and GSEA enrichment analyses revealed that Z5 predominantly affects cell cycle and mitotic cell cycle pathways (Figures 2A-B), with GSEA specifically highlighting its involvement in G2/M phase transition, checkpoint control, and mitotic spindle function (Figure 2C). Notably, transcriptional analysis showed significant downregulation of WEE1 ($\approx$67%) and CDK1 ($\approx$55%), key regulators of the G2/M checkpoint where WEE1 governs CDK1 phosphorylation to control mitotic entry. This was further validated by flow cytometry demonstrating increased G2/M phase accumulation and PHH3 positivity (Figure 2D), coupled with reduced WEE1 and CDC2 phosphorylation alongside elevated phospho-histone H3 levels following Z5 treatment (Figure 2E), collectively indicating G2/M checkpoint disruption.

Subcellular localization analysis (GOCC and GSEA) indicated that Z5 predominantly accumulates in nuclear compartments, replication forks, and chromosomal regions (Figure 2B, Supplementary Figure 2D), consistent with its DNA intercalation properties. Since DNA damage typically triggers the DDR, leading to WEE1-mediated G2/M arrest to facilitate repair, we investigated whether Z5 impairs this protective mechanism. Strikingly, GSEA revealed significant suppression of DNA repair pathways (Supplementary Figure 2E). To validate this, by adopting the well-known DT40-DDR research model(24), we found that the knockdown of key genes involved in DNA repair (e.g., Rev3 in TLR) increased the efficacy of Z5 (Supplementary Figure 2F). These findings suggest that inhibition of DNA repair pathways may play a facilitative role in enhancing Z5's functional activity. Finally,

immunofluorescence microscopy revealed characteristic mitotic catastrophe features

including chromosomal missegregation, multipolar spindle formation, and

micronucleation (Figure 2F). Collectively, these findings demonstrate that Z5 induces

DNA damage while simultaneously disrupting DNA repair mechanisms and G2/M

checkpoint control, ultimately triggering lethal mitotic catastrophe in GBM cells.

Figure 2 Z5 induces G2/M arrest and mitotic catastrophe in GBM cells. (A)

KEGG pathway enrichment analysis and (B)GO enrichment analysis of

downregulated genes identified by the U87-MG microarray. ER: Endoplasmic

Reticulum. (C) GSEA analysis of Cell cycle of G2/M phase transition, G2M

checkpoint, mitotic spindle and cell cycle pathways. (D) Representative flow

cytometric analysis of PHH3+ and DNA contents > 4n cells. (E) The expressions of

WEE1, p-WEE1, PHH3, CDC2, p-CDC2 in GBM cells were measured by

immunoblotting after treatment with different concentrations of Z5 for 48h. (F)

Immunofluorescence staining was performed with anti-tubulin (Red), anti-PHH3

(Green) on the U87-MG and U251-MG cells treated with or without Z5.

3.3 Z5 targets EGFR

To elucidate Z5's mechanism of action, we employed the Connectivity Map (CMAP),

a computational drug repurposing tool that identifies functional connections between

drugs, genes, and diseases by comparing gene expression signatures (29).

Querying CMAP with a signature comprising the top 66 upregulated and top 150

downregulated genes from our microarray data yielded positive connectivity scores

for multiple compounds. Data were categorized by cell type, selecting only compound

perturbagens, and the top 10 compounds per cell type were identified based on

ranking. Statistical analysis revealed EGFR inhibitors as the most frequent functional

matches (Supplementary Tables 2-11, Figure 3A). This computational prediction was

further supported by GSEA analysis showing Z5-mediated inhibition of the

PI3K/AKT/mTOR pathway and mTORC1 activation (Supplementary Figure 2E),

which are well-established pharmacological effects of EGFR inhibitors.

Based on these findings, we hypothesized that Z5 might directly target EGFR. To

test this, we performed a series of biochemical assays. Cellular thermal shift assay

(CETSA) demonstrated that Z5 enhanced the thermal stability of EGFR in both

U87-MG and U251-MG cells (Figure 3B), while drug affinity responsive target

stability (DARTS) assays showed that Z5 protected EGFR from proteolytic

degradation (Figure 3C). Most conclusively, surface plasmon resonance (SPR)

experiments confirmed direct binding between Z5 and the EGFR kinase domain with

a dissociation constant (KD) of 19.6 μM (Figure 3D). Functional studies revealed that

Z5 treatment significantly reduced phosphorylation of EGFR (p-EGFR), ERK

(p-ERK), and mTOR (p-mTOR) in both cell lines, while unexpectedly increasing total

EGFR levels in U251-MG cells (Figure 3E).

To substantiate the interaction between Z5 and EGFR, we evaluated the impact of

EGFR silencing on Z5-induced antiproliferative effects. We first assessed the

knockdown efficiency of EGFR-targeting siRNAs in GBM cell lines, selecting

siEGFR-1261 for subsequent experiments based on its superior efficacy

(Supplementary Figure 3A). Our results demonstrated that siRNA-mediated EGFR

knockdown significantly weakened Z5's proliferative inhibition in both CCK8 and

EdU assays (Figures 3F-G). Furthermore, EGFR silencing abolished Z5-induced

G2/M arrest and suppressed the upregulation of γ-H2AX and PHH3 proteins (Figures

3H-I). Collectively, these data demonstrate that Z5 exerts its anti-GBM effects

through direct EGFR inhibition, leading to disrupted downstream signaling and

ultimately inducing cell cycle arrest and DNA damage responses.

Figure 3 Z5 targets EGFR. (A) In the CMAP data, the top 10 compounds positively

correlated with microarray data were selected for each cell type. The descriptions of

these compounds were then statistically analyzed, and the descriptions were ranked

based on their frequency of occurrence. (B) The CETSA assay was used to evaluate

the binding between Z5 (0.1mM) in thermodynamic levels. The expression of EGFR was detected by immunoblotting. (C) The DARTS assay was used to evaluate the binding between different concentrations of Z5. The expression of EGFR was detected by immunoblotting. (D) Interaction between Z5 and recombinant EGFR kinase domain protein was analyzed by SPR. (E) The expression of EGFR, p-EGFR, ERK, p-ERK, mTOR, p-mTOR in U87-MG and U251-MG cells were measured by immunoblotting after treatment with different concentrations of Z5 for 48h. (F) Growth curves of GBM cell lines transfected with or without si-EGFR and treated with or without Z5 for 48H. (G) The efficacy of Z5 on GBM cell lines transfected with or without si-EGFR was detected by EDU staining. (H) The cell cycle of GBM cell lines transfected with or without si-EGFR was evaluated using flow cytometry after being treated with or without Z5 for 24h. (I) The expression of EGFR, p-EGFR, γ-H2AX and PHH3 in U87-MG and U251-MG cells were measured by immunoblotting after treatment with Z5 for 48h.

3.4 Z5 binds to the E762 residue of EGFR

To elucidate the structural basis of Z5-EGFR binding, we conducted comprehensive molecular docking simulations targeting the ATP-binding pocket of the EGFR kinase domain (PDB: 7KXZ). A detailed analysis of Z5's binding mode revealed key molecular interactions with EGFR: (1) extensive hydrophobic contacts with residues V702, L820, and L694, which stabilize its position within the ATP-binding pocket; and (2) two critical hydrogen bonds formed with K721 and T766, likely contributing to its high binding affinity (Figure 4A).

To experimentally validate these computational predictions, we employed limited proteolysis-mass spectrometry (LiP-MS), a label-free proteomics approach, to map potential Z5 binding sites within the EGFR kinase domain. The LiP-MS results identified several peptide segments within the EGFR kinase domain that may serve as Z5 binding sites (Figures 4B-C). Notably, while the previously identified K721 and T766 residues from the docking studies were not directly detected by LiP-MS, we

observed that K721 forms a hydrogen bond with E738, which may stabilize K721 and

indirectly maintain the hydrogen bond interaction with Z5. By integrating these

findings, we identified E738 (UniProt P00533-1 numbering: E762) as a critical

binding site for Z5.

To functionally validate the importance of E762, we established an ectopic

expression system in HEK293T cells transfected with either empty vector, wild-type

(WT) EGFR, or the E762V mutant EGFR (Figure 4D). Dose-response experiments

using CCK-8 assays demonstrated that Z5's antiproliferative effect reached a plateau

at concentrations >0.1 μM, with residual viability stabilizing around 75% (Figure 4E).

Based on these results, we selected 0.2 μM Z5 for subsequent experiments to ensure

measurable effects while avoiding complete cytotoxicity.

Functional validation using both CCK-8 and EdU assays revealed that the E762V

mutation significantly attenuated Z5's therapeutic effect (Figures 4F-G). Compared to

cells expressing WT-EGFR, those expressing the E762V mutant exhibited markedly

higher cell viability and proliferative capacity following Z5 treatment. These findings

conclusively establish E762 as a key binding residue for Z5 on EGFR, essential for

mediating   its   biological   activity.

Figure 4 Z5 binds to the E762 residue of EGFR. (A) Binding mode of ZYH005 in EGFR kinase domain. Protein residues and ZYH005 are shown as sticks. Carbon atoms in ZYH005 are cyan, and those in protein residues are green. Oxygen and nitrogen atoms are rendered in red and blue, respectively. Black dashed lines indicate hydrogen bonds, with distances labeled in angstroms with yellow background. (B) Red regions indicate unstable peptides after Z5 treatment. Selection criteria: Log2(Fold change) > 2, -Log10(P-value) > 2. (C) Scatter plot showing peptides identified by Lip-MS. Purified EGFR kinase domain protein was treated with 100 μM Z5 at room temperature for 15 minutes, followed by Lip-MS analysis. The scatter plot displays peptide abundance changes between the Z5-treated and control groups. X-axis shows Log2 (Fold change), Y-axis shows -Log10(P-value). (D) The expression of Flag and EGFR in HEK293T cell lines were measured by immunoblotting after transfected with different plasmids. (E) Growth curves of HEK293T cell lines treated

with or without Z5 for 48H. (F) Cell viability was evaluated using CCK-8 kit after

treated with Z5 for 48h. (G) Fluorescent images of proliferating GBM cell lines in

various treatment conditions (green: EDU staining; blue: Hoechst staining).

3.5 WEE1 Overexpression Links to Aggressive GBM and EGFR Interaction

Our previous findings indicated that Z5 targets EGFR and suppresses WEE1-mediated

G2/M phase arrest, thereby promoting entry into mitosis. Furthermore, knockdown of

EGFR abrogated the cell cycle regulatory effects of Z5, suggesting that Z5's inhibition

of WEE1 may occur via an EGFR-dependent mechanism. Through systematic

bioinformatics analysis of the Chinese Glioma Genome Atlas (CGGA) database, we

identified WEE1 as a particularly important player in GBM compared to other glioma

subtypes (Supplementary Figure 4A). Notably, WEE1 expression showed significant

variation among GBM molecular subtypes, with the Classical and Mesenchymal

subtypes exhibiting markedly higher expression than the Proneural subtype

(Supplementary Figure 4B). Furthermore, IDH-wildtype GBMs demonstrated

significantly elevated WEE1 levels compared to their IDH-mutant counterparts

(Supplementary Figure 4C), suggesting a potential link between WEE1

overexpression and the more aggressive GBM phenotype. Comprehensive survival

analyses utilizing both The Cancer Genome Atlas (TCGA) and the CGGA databases

revealed a significant association between elevated WEE1 expression and adverse

clinical outcomes, including reduced overall survival (OS) in GBM patient (Figure 5A;

Supplementary Figures 4D–E). In summary, our data has uncovered the critical role of

WEE1 in GBM and established its significant prognostic value in this aggressive

malignancy.

To validate these findings at the protein level, we performed immunohistochemical

analysis of WEE1 expression in a tissue microarray comprising 64 primary GBM

samples representing all pathological grades (0-IV) and covering diverse brain regions.

Our results demonstrated a clear positive correlation between WEE1 staining intensity

and tumor grade (Figures 5B-C), further supporting WEE1's involvement in GBM

progression.

Next, we investigated the relationship between WEE1 and EGFR. Bioinformatic

analysis of the CGGA cohort demonstrated a statistically significant positive

correlation between WEE1 and EGFR mRNA expression levels (Pearson's R = 0.38)

(Figure 5D). To validate these findings at the protein level, we performed immunofluorescence staining of GBM tumor tissues, which revealed distinct co-localization of EGFR and WEE1 proteins, supporting a potential functional interaction between these two molecules in GBM cells (Figure 5E). These findings provide strong evidence for a functional interaction between EGFR signaling and WEE1-mediated cell cycle regulation in GBM, offering a mechanistic explanation for our observation that Z5's effects on WEE1 are EGFR-dependent.

Figure 5 High Expression of WEE1 Is Correlated with Poor Prognosis in Patients and Positively Associated with EGFR Expression. (A) Association Between WEE1 Expression and Survival Time in CGGA Database. (B) TMA of GBM. (C) Representative images of WEE1 immunohistochemistry on the TMA are shown (original magnification: upper: 5x; lower: 40x). (D) Relationship between EGFR and

431 WEE1 in GBM patients. (E) IF staining images of tumor tissues from GBM patients.

3.6 Z5 inhibits EGFR to disrupt the EGFR-WEE1 axis

Our comprehensive mechanistic studies reveal a novel EGFR-WEE1 signaling axis

that serves as a critical therapeutic target in GBM. To quantitatively characterize the

interaction between WEE1 and EGFR, we performed SPR analysis, which

demonstrated a high-affinity binding between the kinase domains of WEE1 and

EGFR, with an equilibrium dissociation constant (KD) of 17.3 nM (Figure 6A). This

physical interaction was further confirmed by multiple experimental approaches:

immunofluorescence microscopy demonstrated partial nuclear co-localization of

EGFR with predominantly nuclear WEE1 (Figure 6B, Supplementary Figure 5A),

while co-immunoprecipitation assays verified their endogenous interaction in GBM

cells (Figure 6C, Supplementary Figure 5B). Strikingly, Z5 treatment induced

dramatic subcellular redistribution of both proteins - causing WEE1 nuclear export

while promoting EGFR nuclear accumulation - and significantly disrupted their

physical association (Figures 6B-C, Supplementary Figures 5A-B).

The above findings reveal a direct interaction between EGFR and WEE1. This

interaction is specifically inhibited by Z5, which targets residue E762 within the

EGFR kinase domain. To understand the potential role of E762 in EGFR-WEE1

interaction, existing EGFR crystal structures were analyzed. Two distinct

conformations of E762 were found in these structures: an inward-facing orientation

towards the protein core (e.g., in PDB 4WKQ) and an outward-facing orientation (e.g.,

in PDB 6JXT) (Supplementary Figure 6A). We hypothesized that the solvent-exposed

(outward-facing) conformation of E762 is required for EGFR-WEE1 binding, because

only the residues in protein surface can take part in the protein-protein interaction. To

test this hypothesis, two EGFR inhibitors, Gefitinib and AZD9291, were selected to

test their activity toward EGFR-WEE1 interaction inhibition. Based on the crystal

structures, Gefitinib and AZD9291 can stabilize E762 in the inward-facing and

outward-facing conformations, respectively. We predicted that the former inhibitor

would disrupt the EGFR-WEE1 interaction, whereas the latter would not. Surprisingly,

we found that Gefitinib disrupted the interaction between EGFR and WEE1, whereas

AZD9291 enhanced their binding, as revealed by Co-IP (Supplementary Figure 6B).

These results validate our hypothesis that an inward-oriented E762 conformation

impairs the ability of EGFR to interact with WEE1.Therefore, we propose that Z5

exerts its inhibitory effect on the EGFR-WEE1 interaction by the same mechanism. It

can induce or stabilize the inward-facing conformation of E762, thereby preventing

the binding between EGFR and WEE1.

To further validate this signaling axis, we performed genetic and pharmacological

interventions in U87-MG cells. While WEE1 silencing had no effect on EGFR

expression or phosphorylation (p-EGFR), EGFR knockdown significantly reduced

both WEE1 expression and its activating phosphorylation (p-WEE1) (Figure 6D).

Pharmacological validation using targeted inhibitors yielded consistent results:

MK1775 (WEE1 inhibitor) minimally affected EGFR signaling (p-ERK and

p-mTOR), whereas AZD9291 (EGFR inhibitor) potently suppressed both WEE1

phosphorylation and CDC2 activation (p-CDC2) (Figure 6E). These findings establish

EGFR as an upstream regulator of WEE1, defining a unidirectional signaling axis

with functional crosstalk between these kinases.

Given that WEE1 acts downstream of EGFR and Z5 disrupts their interaction, we

hypothesized that WEE1 knockdown would attenuate Z5's therapeutic effects.

siRNA-mediated WEE1 knockdown (siWEE1-1409, Supplementary Figure 3B)

significantly reduced Z5's proliferative inhibition in both CCK8 and EdU assays

(Figures 6F-G, Supplementary Figures 7A-B), abolished Z5-induced G2/M arrest

(Figure 6H, Supplementary Figure 7C), and diminished Z5-mediated upregulation of

γ-H2AX and PHH3 (Figure 6I, Supplementary Figure 7D). These results conclusively

demonstrate that Z5 exerts its anti-GBM effects through targeted disruption of the

EGFR-WEE1 signaling axis.

Figure 6 Z5 inhibits EGFR to disrupt the EGFR-WEE1 axis. (A) SPR analysis of the interaction between the kinase domains of EGFR and WEE1. (B) Confocal immunofluorescence staining was used to analyze the localization of EGFR and WEE1 in U87-MG cells. (C) Co-IP was used to detect the interaction between EGFR and WEE1 after 15 min or untreated Z5 treatment in U87-MG cells. (D)Western blot analysis of WEE1, p-WEE1, CDC2, p-CDC2, EGFR, p-EGFR, ERK, p-ERK, mTOR, and p-mTOR expression levels following WEE1 or EGFR knockdown, (E)or treatment with MK1775 (4 μM) and AZD9291 (8 μM) in U87-MG cells. (F) Growth curves of U87-MG cell lines transfected with or without si-WEE1 and treated with or

without Z5 for 48H. (G) The efficacy of Z5 on U87-MG cell lines transfected with or without si-WEE1 was detected by EDU staining. (H) The cell cycle of U87-MG cell lines transfected with or without si-WEE1 was evaluated using flow cytometry after being treated with Z5 for 24h. (I) The expression of WEE1, p-WEE1, γ-H2AX and PHH3 in U87-MG cells were measured by immunoblotting after treatment with Z5 for 48h.

3.7 Z5 inhibits GSCs tumorigenesis and progression through EGFR-WEE1 axis disruption

GSCs constitute a distinct subpopulation within glioblastoma, characterized by their stem-like properties and heightened capacity for DNA repair, which confers them with an increased resistance to chemotherapy drugs(30, 31). To investigate the efficacy of Z5 in vivo, we first tested its effects in two cell lines of patient-derived GSCs. Under microscopic examination, it became clear that Z5 exerted a substantial effect in inducing the fragmentation of tumor spheres formed by both 3359 and 456 GSCs lines (Figure 7A-B, Supplementary Figures 8A-B). Immunoblot analysis confirmed that Z5 significantly suppressed the EGFR-WEE1 signaling axis in both GSC lines (Figure 7C, Supplementary Figure 8C).

For in vivo validation, we selected the 3359 GSC line to establish an orthotopic xenograft model in mice. When the first untreated (NT) mouse exhibited terminal symptoms, one mouse from each treatment group was euthanized for histological analysis. Hematoxylin and eosin (HE) staining demonstrated that Z5 treatment significantly inhibited GSC tumor growth in the brain (Figure 7D).

Moreover, Z5 notably prolonged the survival of model mice in a dose-dependent manner. The mean survival time of the mice in the control group was determined to be 102.75 days. For the Z5 - treated groups administered with dosages of 10 mg/kg and 20 mg/kg, the mean survival times of the mice reached 127.5 days and 139 days, representing increases of 24.1% and 35.3% relative to that of the control group, respectively (Figure 7E). IHC staining also demonstrated a significant reduction in EGFR and WEE1 expression within tumors following Z5 treatment (Figure 6F, Supplementary Figures 8D-E). Furthermore, following 8 weeks of Z5 treatment, the results of HE staining showed no signs of toxicity in the heart, liver, spleen, lungs, and kidneys of the mice (Supplementary Figure S9). These findings demonstrate that

Z5 not only effectively inhibits the growth of GSCs in vivo but is also sufficiently

safe.

These collective findings establish Z5 as a potent EGFR inhibitor that exerts its

anti-glioblastoma effects through a precisely orchestrated mechanism. Z5 initially

targets and binds to the E762 residue of EGFR, which serves as the first step in

initiating downstream molecular events. This interaction subsequently leads to the

induction of DNA damage and impairs the cellular DNA repair machinery.

Concurrently, Z5 disrupts the critical EGFR-WEE1 protein−protein interaction,

further compromising the function of WEE1 — a key regulator of the G2/M

checkpoint. The combined disruption of DNA repair and WEE1 signaling culminates

in mitotic catastrophe and tumor cell death (Figure 7G). The therapeutic potential of

this multi-targeted mechanism is robustly demonstrated by Z5's strong anti-tumor

activity across a range of experimental models, including GBM cell lines,

patient-derived GSCs, and orthotopic GSC-derived xenografts in mice.

Figure 7 Z5 inhibits GSCs tumorigenesis and progression through EGFR-WEE1 axis disruption. (A) Microscopic observation of GSC-derived tumor sphere formation in 3359 cells after incubation with different concentrations of Z5 for 48 hours. (B) Quantitative analysis of the fragmentation of tumor spheres from (A). Data are presented as the mean ± SD, n=3, ****p < 0.0001, compared with "0" group. (C) The

expressions level of γ-H2AX, WEE1, p-WEE1, PHH3, CDC2, p-CDC2, EGFR,

p-EGFR, ERK, p-ERK, mTOR, p-mTOR in 3359 treated with or without Z5. (D)

H&E staining to evaluate intracranial tumor formation. (E) Survival analysis of mice

with orthotopically transplanted GSCs. Data are presented as the mean ± SD, n=4, *p

< 0.05, compared with NT group. (F) Immunohistochemistry examination of EGFR

and WEE1 expression in orthotopic xenografts in mice. (G) Detailed molecular

mechanisms of Z5-mediated anti-GBM effects through targeting EGFR and WEE1.

Discussion

Since TMZ's approval in 2005, despite extensive research, no transformative GBM

therapies have emerged. While tumor-treating fields, molecularly targeted agents (e.g.,

EGFR/VEGF inhibitors), and immunotherapy have been integrated into clinical

practice, their efficacy is limited by tumor heterogeneity, immunosuppressive

microenvironment, and BBB exclusion, resulting in high recurrence rates (>90%)(32,

33). This unmet need drives our identification of Z5, a potent anti-GBM agent with

demonstrated safety. We elucidated its mechanism as an EGFR inhibitor and validated

its therapeutic efficacy.

Phenanthridinone-derived natural products have demonstrated promising

anti-tumour properties through EGFR-related mechanisms. For instance, lycorine

induces apoptosis in GBM cells via EGFR inhibition and exhibits favorable

therapeutic efficacy in patient-derived GBM xenograft models(34). Similarly,

narciclasine suppresses gastric cancer cell proliferation by modulating the

AKT/mTOR signaling pathway(35) , while also functioning as a TOP1 inhibitor that

induces G2/M phase arrest and promotes apoptosis in cancer cells(36). Notably,

narciclasine demonstrates remarkable therapeutic efficacy at low dosages—extending

survival in orthotopic GBM mouse models at just 1 mg/kg(37, 38). These findings

highlight the therapeutic potential of the phenanthridone scaffold, which may

simultaneously engage EGFR targeting and DNA intercalation

mechanisms. Importantly, Z5, as a representative of this scaffold, not only inherits

these pharmacological features but also demonstrates potent anti-GBM efficacy.

Conventional EGFR inhibitors (gefitinib, osimertinib) show limited GBM efficacy

due to tumor heterogeneity, redundant pathways, and BBB penetration challenges(15, 39, 40). Our studies reveal Z5's unique approach: direct binding to EGFR's E762 residue disrupts its kinase activity while subsequently inducing conformational changes that prevent EGFR-WEE1 interaction. This effect addresses two critical vulnerabilities in GBM—aberrant EGFR signaling and compromised cell cycle checkpoint control. Unlike nuclear EGFR targeting strategies that focus on downstream oncogene upregulation(41, 42), Z5's mechanism combines immediate kinase inhibition with sustained disruption of DNA repair pathways through WEE1 modulation. This is particularly relevant as GBM cells rely on EGFR amplification to drive proliferation and radiation resistance while depending on WEE1 to survive replication stress.

Using single-molecule magnetic tweezers and cell models, we previously confirmed that Z5 is a DNA intercalator(22). DNA intercalators reversibly bind to double-stranded DNA (dsDNA) through non-covalent interactions—such as van der Waals forces, hydrogen bonds, hydrophobic effects, and charge-transfer interactions—causing structural changes that affect DNA stability and its interaction with proteins Unlike alkylating agents, which cause irreversible DNA damage via covalent bonding, intercalators must first form a relatively stable complex with DNA to exert cytotoxic effects. These complexes can interfere with DNA replication, transcription, and repair by disrupting the function of DNA-associated enzymes(43-45). Unlike alkylating agents, which cause irreversible DNA damage via covalent bonding, intercalators must first form a relatively stable complex with DNA to exert cytotoxic effects. These complexes can interfere with DNA replication, transcription, and repair by disrupting the function of DNA-associated enzymes. Anthracyclines like doxorubicin are classic examples; although they intercalate into DNA, their main cytotoxic effect comes from topoisomerase II inhibition, leading to DNA breaks and cell death. Compared to strong intercalators such as YOYO-1 and ethidium bromide, Z5 exhibits moderate intercalation strength. This suggests it may have lower mutagenic and carcinogenic risks. Indeed, toxicity studies in various normal cells and animal models have shown that Z5 has low cytotoxicity(22). In this study, long-term toxicity assessment (over 150 days) in a GSC-derived orthotopic GBM

mouse model further supported this finding.

Our investigation reveals that Z5 exerts its anti-GBM effects through a multifaceted

mechanism targeting EGFR. Specifically, Z5 initially binds to the E762 residue within

the kinase domain of EGFR, which leads to subsequent induction of DNA

double-strand breaks (DSBs). This is followed by disruption of the critical interaction

between EGFR and WEE1. This sequential mode of action aligns with the molecular

pathology of GBM. The therapeutic rationale for Z5 is further strengthened by

WEE1's critical role in cancer biology. As a key cell-cycle checkpoint kinase, WEE1

phosphorylates CDK1/2 to enforce G2/M arrest, allowing time for DNA repair before

mitosis. In cancer cells, WEE1 overexpression correlates with poor prognosis and

therapeutic resistance, while its inhibition forces mitotic catastrophe in genomically

unstable cells(46). Given that GBM cells critically depend on WEE1 to survive

replication stress induced by EGFR amplification and radiation therapy, Z5's ability to

simultaneously target EGFR and disrupt WEE1-mediated checkpoint control provides

a mechanistically sound and clinically compelling therapeutic approach.

Our study has several limitations. Although functional crosstalk between EGFR and

WEE1 in DNA damage response is established, the structural basis of their interaction

remains poorly defined (7, 47, 48). Our data demonstrate that Z5 binding to EGFR's

E762 residue disrupts their association, but the precise binding interface - including

whether WEE1 engages EGFR through single or multiple contact points - remains to

be elucidated. Additionally, the conformational changes induced by Z5 at E762 and

their direct impact on WEE1's kinase activity require structural validation through

co-crystallization studies. The temporal relationship between EGFR inhibition, WEE1

disruption, and DNA damage induction also warrants clarification. Comparative

studies in other cancers provide intriguing insights: while combined EGFR and WEE1

inhibition shows limited efficacy in esophageal squamous cell carcinoma (ESCC) (49),

synergistic effects have been observed in leptomeningeal carcinomatosis models(50).

These observations underscore the complexity of EGFR-WEE1 interactions across

different cancer types and highlight the need for cancer-specific therapeutic strategies.

In conclusion, Z5's unique mechanism—initiating EGFR targeting at the E762 residue, which sequentially induces DNA damage, disrupts EGFR-WEE1 interaction, and compromises DNA repair pathways—offers a paradigm shift in GBM therapy by simultaneously addressing two critical vulnerabilities: aberrant proliferation signaling and genomic instability. Our work establishes a framework for phenanthridone derivatives as multi-mechanistic anti-GBM agents, warranting further clinical translation.

Ethics

GSC cells were obtained from glioma patients who underwent surgery at the Department of Neurosurgery of Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology. All participants provided written informed consent and the study was approved by the Ethics Committee of Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology (Serial number: 2021-lEC-A244). The Animal Experiment Administration Committee of the Huazhong University of Science and Technology (HUST) approved all animal experiments to ensure ethical and humane treatment of animals (IACUC Number:3028).

Consent for publication

Not applicable.

Availability of Data and Materials

This study did not generate new regents or original code. All data generated or analyzed during this study are included in this article and its supplementary information files. Microarray data can be accessed through the following link: https://ngdc.cncb.ac.cn/omix/preview/BlYvj2iS.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was financially supported by the by the National Natural Science

Foundation of China [grant number 82073886], the Program for Medical Youth Talent of Hubei Province (2024-2027), Hubei Provincial Administration of Traditional Chinese Medicine Research Fund [grant number ZY2023M063], the National Key R&D Program of China [grant number 2021YFA0910500] and National Natural Science Foundation of China [grant number 82473132 and 82072805].

Authors' contributions

Yonghui Zhang and Qingyi Tong conceived the project. Jianzheng Huang performed most of the experiments. Qingyi Tong and Jianzheng Huang prepared the figures, analyzed the data and wrote the manuscript. Zijun Zhang, Yang Xiao, Ziming Zhao and Zengwei Luo participated in some of the experiments. Jianzheng Huang, Chao Song, Xingjiang Yu, Suojun Zhang and Shouchang Feng were responsible for the animal experiments. All authors have read and approved the final manuscript.

Acknowledgements

We thank Dr. Shideng Bao, Dr. Jeremy Rich and Professor Xingjiang Yu for generously providing GSCs (T3359 and D456). We thank the Medical Subcenter of HUST Analytical & Testing Center for acquiring the data, the Experimental Animal Centre of HUST for providing the animal experimentation facilities.

References

1. Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, Reifenberger G. Glioma. Nature Reviews Disease Primers. 2024;10(1):33.

2. Grochans S, Cybulska AM, Simińska D, Korbecki J, Kojder K, Chlubek D, Baranowska-Bosiacka I. Epidemiology of Glioblastoma Multiforme-Literature Review. Cancers. 2022;14(10).

3. Alick P WJJ. A Review of Glioblastoma and Other Primary Brain Malignancies. 2023;330(2).

4. Rodriguez SMB, Kamel A, Ciubotaru GV, Onose G, Sevastre AS, Sfredel V, Danoiu S, Dricu A, Tataranu LG. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma. Int J Mol Sci. 2023;24(13).

5. Lin B, Ziebro J, Smithberger E, Skinner KR, Zhao E, Cloughesy TF, Binder ZA, O'Rourke DM, Nathanson DA, Furnari FB, Miller CR. EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro Oncol. 2022;24(12):2035-2062.

6. Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translocation modulates DNA repair

following cisplatin and ionizing radiation treatment. Cancer Res. 2011;71(3):1103-1114.

7. Zhou Z, Lu H, Zhu S, Gomaa A, Chen Z, Yan J, Washington K, El-Rifai W, Dang C, Peng D. Activation of EGFR-DNA-PKcs pathway by IGFBP2 protects esophageal adenocarcinoma cells from acidic bile salts-induced DNA damage. J Exp Clin Cancer Res. 2019;38(1):13.

8. Meyn RE, Munshi A, Haymach JV, Milas L, Ang KK. Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol. 2009;92(3):316-322.

9. Rajput M, Singh R, Singh N, Singh RP. EGFR-mediated Rad51 expression potentiates intrinsic resistance in prostate cancer via EMT and DNA repair pathways. Life Sci. 2021;286:120031.

10. Prewett M, Deevi DS, Bassi R, Fan F, Ellis LM, Hicklin DJ, Tonra JR. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res. 2007;13(24):7432-7440.

11. Justin T, Nishika K, Jian L C. Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future Directions. Cells. 2025;14(7).

12. Chen Z, Vallega KA, Wang D, Quan Z, Fan S, Wang Q, Leal T, Ramalingam SS, Sun SY. DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. J Clin Invest. 2024;134(10).

13. Lee MJ, Ye AS, Gardino AK, Heijink AM, Sorger PK, MacBeath G, Yaffe MB. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell. 2012;149(4):780-794.

14. An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies. Oncogene. 2018;37(12):1561-1575.

15. Li X-P, Guo Z-Q, Wang B-F, Zhao M. EGFR alterations in glioblastoma play a role in antitumor immunity reg ulation. Front Oncol;13.

16. Jin Z, Yao G. Amaryllidaceae and Sceletium alkaloids. Natural Product Reports. 2019.

17. Azad I, Ahmad R, Khan T, Saquib M, Hassan F, Akhter Y, Khan AR, Nasibullah M. Phenanthridine derivatives as promising new anticancer agents: synthesis, biological evaluation and binding studies. Future medicinal chemistry. 2020;12(8):709-739.

18. Ingrassia L, Lefranc F, Dewelle J, Pottier L, Mathieu V, Spiegl-Kreinecker S, Sauvage S, El Yazidi M, Dehoux M, Berger WJJomc. Structure– activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. Journal of Medicinal Chemistry 2009;52(4):1100-1114.

19. Van Goietsenoven G, Mathieu V, Lefranc F, Kornienko A, Evidente A, Kiss R. Narciclasine as well as other Amaryllidaceae Isocarbostyrils are Promising GTP-ase Targeting Agents against Brain Cancers. Medicinal research reviews. 2013;33(2):439-455.

20. F ü rst RJPm. Narciclasine – an amaryllidaceae alkaloid with potent antitumor and anti-inflammatory properties. Planta medica. 2016;82(16):1389-1394.

21. Yuan M, Chen L, Wang J, Chen S, Wang K, Xue Y, Yao G, Luo Z, Zhang Y. Transition-metal-free synthesis of phenanthridinones from biaryl-2-oxamic acid under radical conditions. Organic Letters. 2015;17(2):346-349.

22. Tong Q, You H, Chen X, Wang K, Sun W, Pei Y, Zhao X, Yuan M, Zhu H, Luo Z, Zhang Y.

752   ZYH005, a novel DNA intercalator, overcomes all-trans retinoic acid resistance in acute
753   promyelocytic leukemia. Nucleic Acids Res. 2018;46(7):3284-3297.

754   23.   Liu D, Zhu H, Cheng L, Li R, Ma X, Wang J, Wang J, Zhang S, Li Y, Shu K, Yu X, Li C.
755   Hypoxia-induced galectin-8 maintains stemness in glioma stem cells via autophagy regulation.
756   Neuro Oncol. 2024;26(5):872-888.

757   24.   Wu X, Takenaka K, Sonoda E, Hochegger H, Kawanishi S, Kawamoto T, Takeda S, Yamazoe
758   M. Critical roles for polymerase zeta in cellular tolerance to nitric oxide-induced DNA
759   damage. Cancer Res. 2006;66(2):748-754.

760   25.   Beyett TS, Rana JK, Schaeffner IK, Heppner DE, Eck MJ. Structural Analysis of the
761   Macrocyclic Inhibitor BI-4020 Binding to EGFR Kinase. ChemMedChem.
762   2024;19(12):e202300343.

763   26.   Unni S, Huang Y, Hanson RM, Tobias M, Krishnan S, Li WW, Nielsen JE, Baker NA. Web
764   servers and services for electrostatics calculations with APBS and PDB2PQR. J Comput
765   Chem. 2011;32(7):1488-1491.

766   27.   Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ.
767   AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J
768   Comput Chem. 2009;30(16):2785-2791.

769   28.   Malinovska L, Cappelletti V, Kohler D, Piazza I, Tsai TH, Pepelnjak M, Stalder P, Dorig C,
770   Sesterhenn F, Elsasser F, Kralickova L, Beaton N, Reiter L, de Souza N, Vitek O, Picotti P.
771   Proteome-wide structural changes measured with limited proteolysis-mass spectrometry: an
772   advanced protocol for high-throughput applications. Nat Protoc. 2023;18(3):659-682.

773   29.   Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP,
774   Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ,
775   Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The Connectivity Map: using
776   gene-expression signatures to connect small molecules, genes, and disease. Science.
777   2006;313(5795):1929-1935.

778   30.   Gimple RC, Bhargava S, Dixit D, JN R. Glioblastoma stem cells: lessons from the tumor
779   hierarchy in a lethal cancer. Genes Dev. 2019;33(11-12):591-609.

780   31.   Suva ML, Tirosh I. The Glioma Stem Cell Model in the Era of Single-Cell Genomics. Cancer
781   Cell. 2020;37(5):630-636.

782   32.   Liu Y, Zhou F, Ali H, Lathia JD, Chen P. Immunotherapy for glioblastoma: current state,
783   challenges, and future perspectives. Cellular & Molecular Immunology.
784   2024;21(12):1354-1375.

785   33.   Davis ME. Glioblastoma: Overview of Disease and Treatment. Clinical journal of oncology
786   nursing. 2016;20(5 Suppl):S2-8.

787   34.   Shen J, Zhang T, Cheng Z, Zhu N, Wang H, Lin L, Wang Z, Yi H, Hu M. Lycorine inhibits
788   glioblastoma multiforme growth through EGFR suppression. J Exp Clin Cancer Res.
789   2018;37(1):157.

790   35.   Yuan Y, He X, Li X, Liu Y, Tang Y, Deng H, Shi X. Narciclasine induces autophagy-mediated
791   apoptosis in gastric cancer cells through the Akt/mTOR signaling pathway. BMC Pharmacol
792   Toxicol. 2021;22(1):70.

793   36.   Wang M, Liang L, Wang R, Jia S, Xu C, Wang Y, Luo M, Lin Q, Yang M, Zhou H, Liu D,
794   Qing C. Narciclasine, a novel topoisomerase I inhibitor, exhibited potent anti-cancer activity
795   against cancer cells. Nat Prod Bioprospect. 2023;13(1):27.

796   37.   Lefranc F, Sauvage S, Van Goietsenoven G, Megalizzi V, Lamoral-Theys D, Debeir O,
797   Spiegl-Kreinecker S, Berger W, Mathieu V, Decaestecker C, Kiss R. Narciclasine, a plant
798   growth modulator, activates Rho and stress fibers in glioblastoma cells. Mol Cancer Ther.
799   2009;8(7):1739-1750.

800   38.   Van Goietsenoven G, Mathieu V, Lefranc F, Kornienko A, Evidente A, Kiss R. Narciclasine as
801   well as other Amaryllidaceae isocarbostyrils are promising GTP-ase targeting agents against
802   brain cancers. Med Res Rev. 2013;33(2):439-455.

803   39.   Lee A, Arasaratnam M, Chan DLH, Khasraw M, Howell VM, Wheeler H. Anti-epidermal
804   growth factor receptor therapy for glioblastoma in adults. The Cochrane database of
805   systematic reviews. 2020;5(5):Cd013238.

806   40.   Westphal M, Maire CL, Lamszus K. EGFR as a Target for Glioblastoma Treatment: An
807   Unfulfilled Promise. CNS Drugs. 2017;31(9):723-735.

808   41.   Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to
809   cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer.
810   2006;94(2):184-188.

811   42.   Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL. Nuclear EGFR as a
812   molecular target in cancer. Radiother Oncol. 2013;108(3):370-377.

813   43.   Martinez R, Chacón-García. L. The search of DNA-intercalators as antitumoral drugs: what it
814   worked and what did not work. Current Medicinal Chemistry. 2005;12:127-151.

815   44.   Venugopal S, Sharma V, Mehra A, Singh I, Singh G. DNA intercalators as anticancer agents.
816   Chem Biol Drug Des. 2022;100(4):580-598.

817   45.   Biebricher AS, Heller I, Roijmans RFH, Hoekstra TP, Peterman EJG, Wuite GJL. The impact
818   of DNA intercalators on DNA and DNA-processing enzymes elucidated through
819   force-dependent binding kinetics. Nature communications. 2015;6(1):7304.

820   46.   Ghelli Luserna di Rorà A, Cerchione C, Martinelli G, Simonetti G. A WEE1 family business:
821   regulation of mitosis, cancer progression, and therapeutic target. Journal of hematology &
822   oncology. 2020;13(1):126.

823   47.   Cetin MH, Rieckmann T, Hoffer K, Riepen B, Christiansen S, Gatzemeier F, Feyerabend S,
824   Schoof M, Schuller U, Petersen C, Mynarek M, Rothkamm K, Kriegs M, Struve N. G2
825   checkpoint targeting via Wee1 inhibition radiosensitizes EGFRvIII-positive glioblastoma cells.
826   Radiat Oncol. 2023;18(1):19.

827   48.   Volman Y, Hefetz R, Galun E, Rachmilewitz J. DNA damage alters EGFR signaling and
828   reprograms cellular response via Mre-11. Sci Rep. 2022;12(1):5760.

829   49.   Chen D, Hong R, Cao Y, Wu Q, Wang Y, Chen J, Li J, Zhang W, Zhan Q. Combined Wee1 and
830   EGFR inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma.
831   Carcinogenesis. 2023;44(6):451-462.

832   50.   Fukuda K, Nanjo S, Takeuchi S, Chakrabarti T, Brown T, Dev Sahadevan SW, Arai S, Sato S,
833   Kotani H, Nishiyama A, Sakaguchi H, Ohtsubo K, Taniguchi H, Blakely CM, Bivona TG,
834   Yano S. Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in
835   EGFR-mutant lung cancer. J Thorac Oncol. 2025.